Nuveen’s Foghorn Therapeutics FHTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$241K Buy
50,378
+245
+0.5% +$1.34K ﹤0.01% 3056
2025
Q4
$271K Hold
50,133
﹤0.01% 3072
2025
Q3
$245K Hold
50,133
﹤0.01% 3104
2025
Q2
$236K Sell
50,133
-10,305
-17% -$43.1K ﹤0.01% 3118
2025
Q1
$221K Hold
60,438
﹤0.01% 3115
2024
Q4
$285K Hold
60,438
﹤0.01% 3138
2024
Q3
$563K Sell
60,438
-7,428
-11% -$53.8K ﹤0.01% 2976
2024
Q2
$390K Buy
67,866
+13,903
+26% +$82.8K ﹤0.01% 3074
2024
Q1
$362K Hold
53,963
﹤0.01% 3060
2023
Q4
$348K Buy
53,963
+483
+0.9% +$2.08K ﹤0.01% 3113
2023
Q3
$267K Hold
53,480
﹤0.01% 2986
2023
Q2
$376K Hold
53,480
﹤0.01% 2983
2023
Q1
$332K Sell
53,480
-483
-0.9% -$3.16K ﹤0.01% 2894
2022
Q4
$345K Sell
53,963
-3,090
-5% -$23.3K ﹤0.01% 2961
2022
Q3
$490K Sell
57,053
-2,551
-4% -$32.8K ﹤0.01% 2963
2022
Q2
$811K Sell
59,604
-53,270
-47% -$687K ﹤0.01% 2882
2022
Q1
$1.52M Buy
112,874
+65,887
+140% +$904K ﹤0.01% 2639
2021
Q4
$837K Sell
46,987
-6,587
-12% -$94.7K ﹤0.01% 2914
2021
Q3
$709K Sell
53,574
-2,836
-5% -$31.4K ﹤0.01% 3098
2021
Q2
$602K Buy
56,410
+44,603
+378% +$486K ﹤0.01% 3140
2021
Q1
$156K Hold
11,807
﹤0.01% 3258
2020
Q4
$239K Buy
+11,807
New +$226K ﹤0.01% 3177

Other funds holding FHTX

Nuveen's FHTX Position: Q1 2026 in Review

Nuveen increased its Foghorn Therapeutics (FHTX) stake by 0.49% in Q1 2026, buying an estimated $1.34K and bringing the position to 50,378 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #3056.

Nuveen first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.52M in Q1 2022. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Nuveen held 50,378 shares of Foghorn Therapeutics worth $241K as of Q1 2026.
  • Nuveen bought 245 Foghorn Therapeutics shares in Q1 2026, an estimated $1.34K.
  • Foghorn Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #3056 holding.
  • Nuveen first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Nuveen's Foghorn Therapeutics position peaked at $1.52M in Q1 2022.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.